SpringWorks Therapeutics has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for nirogacestat, an oral inhibitor for treating desmoid tumours or deep fibromatosis in adult patients.

The federal agency awarded the designation based on Phase I and Phase II clinical trials of the drug.

Breakthrough therapy designation facilitates the development and regulatory review of medicines for treating serious ailments.

The FDA awarded nirogacestat Orphan Drug Designation in June last year, followed by Fast Track Designation in November.

Nirogacestat is an oral, selective, small-molecule gamma-secretase inhibitor. It is intended to treat patients with progressive, unresectable, recurrent or refractory desmoid tumours or deep fibromatosis.

Currently, the drug is in Phase III clinical development.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the Phase I and Phase II clinical trials, nirogacestat was investigated in 24 patients. According to the company, it demonstrated a 100% disease control rate as measured by RECIST criteria.

SpringWorks CEO Saqib Islam said: “We are committed to pursuing the rapid development of nirogacestat given the important need for new therapies for patients with desmoid tumours and are pleased to receive this breakthrough therapy designation.

“We are currently enrolling adult patients in our Phase III DeFi trial and will continue to work closely with the FDA with the goal of bringing nirogacestat to patients as quickly as possible.”

Desmoid tumours, also referred to as aggressive fibromatosis or desmoid-type fibromatosis, are disfiguring soft tissue tumours occurring in any part of the body.

However, they generally occur in the upper and lower extremities, abdominal walls, thoracic areas and the head and neck.

It causes severe pain, internal bleeding, limits a range of motion and may turn fatal in rare cases.

Desmoid tumours typically occur in patients in the age group of 15 to 60 years. Around 1,000 to 1,500 new cases are diagnosed every year in the US.

Currently, there are no FDA-approved therapies to treat these non-malignant tumours.